Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Prozac In Ocean Water A Possible Threat To Sea Life, Study Finds

By PORTLAND STATE UNIVERSITY | October 25, 2017

Oregon shore crabs exhibit risky behavior when they’re exposed to the antidepressant Prozac, making it easier for predators to catch them, according to a new study from Portland State University (PSU).

The study, published in the journal Ecology and Evolution, illustrates how concentrations of pharmaceuticals found in the environment could pose a risk to animal survival.

For years, tests of seawater near areas of human habitation have shown trace levels of everything from caffeine to prescription medicines. The chemicals are flushed from homes or medical facilities, go into the sewage system, and eventually make their way to the ocean.

In a laboratory, the PSU team exposed Oregon shore crabs to traces of fluoxetine, the active ingredient in Prozac. They found that the crabs increased their foraging behavior, showing less concern for predators than they normally would. They even did so during the day, when they would normally be in hiding.

They also fought more with members of their own species, often either killing their foe or getting killed in the process.

“The changes we observed in their behaviors may mean that crabs living in harbors and estuaries contaminated with fluoxetine are at greater risk of predation and mortality,” said researcher Elise Granek, a professor in PSU’s department of Environmental Sciences and Management.


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE